Navigation Links
Anadys Pharmaceuticals Reports Third Quarter 2007 Financial Results and Operational Highlights
Date:11/1/2007

/p>

restructuring were the decisions to discontinue further development of

ANA380, a nucleotide analog for the treatment of hepatitis B virus

(HBV) infection, halt all work on early discovery projects, and effect

an immediate reduction in force of approximately one-third of the

Company's employees, with several additional positions to be eliminated

in early 2008.

Recent Scientific Presentations

-- Reported ANA773 Dose Schedule Data. On October 25, 2007, Anadys

presented preclinical data on ANA773 during a poster session at the

2007 AACR-NCI-EORTC International Conference on Molecular Targets and

Cancer Therapeutics. The report showed the impact that varying the

dosing schedule has on the pharmacodynamic response to ANA773, a

prodrug of a toll-like receptor 7 agonist. Specifically, the report

described that immunostimulatory responses to ANA773 in vivo can be

modulated by schedule of administration.

-- Reported ANA598 Preclinical Data. On September 11, 2007, Anadys

presented preclinical data on ANA598, a non-nucleoside inhibitor of the

HCV NS5B polymerase, during a poster session at the 14th International

Symposium on Hepatitis C Virus and Related Viruses. The report

characterized the favorable antiviral, metabolic, pharmacokinetic and

preliminary toxicologic properties that supported the decision

announced in June to progress ANA598 to IND enabling studies and

subsequent clinical evaluation expected to commence in the second

quarter of 2008.

Webcast of Conference Call

Anadys will host a conference call today at 5:00 p.m. Eastern Daylight Time to discuss its third quarter financial results and operational highlights and to give an update on its programs. A live webcast of the call will be available online at '/>"/>

SOURCE Anadys Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Deltanoid Pharmaceuticals begins phase II osteoporosis study
2. The Coming of Biotech Generic Pharmaceuticals
3. TomoTherapy reports 86% revenue jump, $131M net loss in Q1
4. Sonic Foundry reports GAAP loss as Q2 revenues rise
5. Fiserv reports $113.5 million in Q1 profit
6. Third Wave reports net loss of $18.9M for 2006
7. Musicnotes reports 45 percent growth in 2006
8. Sonic Foundry reports net loss, higher revenue
9. Sonic Foundry reports first cash-positive quarter
10. Merge Healthcare reports $10.8M net loss in Q3
11. Third Wave reports $5.2M third quarter loss
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/16/2013)... May 16, 2013 ISPE ... A. Myers, CAE, to the newly created position ... new role, Myers will be responsible for stimulating ... production strategies, advancing the Society’s Member-led and staff-driven ... continuing to refine organizational, membership and product marketing. ...
(Date:5/16/2013)... Kitware , a leading provider ... Phase II SBIR funding from the U.S. Department ... open-source, high performance computing (HPC) simulation and computation ... to select only the toolkits and applications needed ... analysis tasks. , Manufacturers increasingly rely on ...
(Date:5/16/2013)... Canada (PRWEB) May 16, 2013 On ... and costs over one billion dollars. Despite this investment, ... With stakes this high, is your clinical trial design ... deliver the best outcomes? , Dr. Frederic Sax, Global ... will discuss the use of data, information and technology ...
(Date:5/16/2013)... (PRWEB) May 16, 2013 Dr. Stephen ... a tutorial titled “Nanoimprint Lithography and Applications” at IEEE ... , Nanoimprint, invented in 1995 by Chou, is becoming ... to a unique combination of sub-10 nm resolution, large ... Nanoimprint is impacting both R&D and manufacturing in a ...
Breaking Biology Technology:ISPE Names Barbara A. Myers, CAE, as Vice President of Professional Development 2Kitware Develops a Customizable Simulation Framework to Provide HPC for Small to Mid-Sized Manufacturers 2Optimizing Clinical Trials Outcomes through Computer Assisted Design, New Life Science Webinar Hosted by Xtalks 2Founder, Prof. Stephen Chou to Give Tutorial on Nanoimprint at IEEE Nano 2013 2
... Now Able to Detect a Single Cancer Cell Through In Vivo ... ... Caliper Life,Sciences, Inc. (Nasdaq: CALP ) today introduced Bioware(R) Ultra ... for in vivo imaging applications. Bioware Ultra cell lines are,10 to 100 ...
... April 15 Pittsburgh-based Foundation,Radiology Group (FRG), ... to interpret diagnostic images for hospitals,announced today ... appointed to the,position of Chief Medical Officer. ... of a nationwide network of radiology physician ...
... 15 , What and When, Additional ... in Atherosclerosis using pioGlitazOne) published,today in Circulation revealed ... ACTOS(R) (pioglitazone HCl) was,associated with increased levels of ... glimepiride., The increased effect on HDL-C levels ...
Cached Biology Technology:Increased Light Leads to Early Detection: Caliper Life Sciences Introduces Bioware(R) Ultra Cancer Cell Lines 2Increased Light Leads to Early Detection: Caliper Life Sciences Introduces Bioware(R) Ultra Cancer Cell Lines 3James W. Backstrom, M.D., Named Chief Medical Officer of Foundation Radiology Group 2James W. Backstrom, M.D., Named Chief Medical Officer of Foundation Radiology Group 3New Data Published in Circulation Showed an Increase in HDL Cholesterol Levels with ACTOS(R) (pioglitazone HCl) 2New Data Published in Circulation Showed an Increase in HDL Cholesterol Levels with ACTOS(R) (pioglitazone HCl) 3
(Date:5/17/2013)... Atlanta residents of all ages will celebrate the ... impact on our daily lives during the inaugural ... engineers and educators from local museums, corporations, K-12 ... than 40 different events for children and adults ... http://atlantasciencefestival.org . , The annual Atlanta ...
(Date:5/17/2013)... of American Societies for Experimental Biology (FASEB) released a ... (NIH) funding trends highlighting the devastating impact of sequestration ... FASEB analysis follows a May 15th Senate Appropriations Committee ... testified that the $1.6 billion cut the agency sustained ... substantial impact on the scientific community." , According ...
(Date:5/16/2013)... fast food restaurant had a higher body mass index ... food, according to researchers at The University of Texas ... strong among those with a lower income. , ... Journal of Public Health indicates higher BMI associates ... among lower-income African-Americans, the density, or number, of fast ...
Breaking Biology News(10 mins):First Atlanta Science Festival set for 2014 2Body mass index of low income African-Americans linked to proximity of fast food restaurants 2Body mass index of low income African-Americans linked to proximity of fast food restaurants 3
... University and the University of Maryland have identified a ... invertebrate. , Finicky mating behavior appears to be the ... cricket, the scientists wrote in the Jan. 27 issue ... detect tiny differences in the pulse rates of male ...
... led by University of Illinois at Chicago professor S. Jay ... United States later this century. , That prediction, which is ... people and minorities, is from a special report appearing in ... Medicine. , The study determines that obesity currently reduces life ...
... from the first clinical trial of a therapeutic cancer ... (ProMuneTM, Coley Pharmaceutical), with a peptide antigen were reported ... shows that the CpG 7909 DNA sequence is safe, ... destroy cancer cells. The Phase I study was conducted ...
Cached Biology News:Cricket's finicky mating behavior boosts biodiversity 2Cricket's finicky mating behavior boosts biodiversity 3US life expectancy about to decline, researchers say 2US life expectancy about to decline, researchers say 3Pathogen-Mimicking Vaccine As Strategy For Cancer Therapy 2
Anti-MMP-14, catalytic domain, clone LEM-2/15.8 Immunogen: Synthetic peptide: amino acid sequence 218-233 within the catalytic domain Available Date: 38579...
Rabbit polyclonal to Raf1 ( Abpromise for all tested applications). entrezGeneID: 5894 SwissProtID: P04049...
Rabbit anti MMP-13, Hinge Region MMP-13 Hinge Region...
Rabbit polyclonal to MAP3K12 ( Abpromise for all tested applications). Antigen: Synthetic peptide conjugated to KLH from the C-terminal region of human MAP3K12 Entrez Gene ID: 7786 Swiss ...
Biology Products: